Oculis Holding
OCS
20 hedge funds and large institutions have $94.7M invested in Oculis Holding in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 2 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
67% more funds holding
Funds holding: 12 → 20 (+8)
60% more capital invested
Capital invested by funds: $59.4M → $94.7M (+$35.4M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% more ownership
Funds ownership: 8.37% → 10.37% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$11.5M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$6.61M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$4.99M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.69M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$389K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$225K |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$179K |
OCS Hedge Fund Activity: Q1 2025 in Review
20 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q1 2025, worth a combined $94.7M — up 60% from $59.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OCS positions and 2 closed out — a net gain of 8 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Pivotal bioVenture Partners Investment Advisor, adding an estimated $11.5M. The largest seller was Citadel Advisors, exiting entirely with an estimated $389K sold.
- 20 institutional investors held Oculis Holding (OCS) as of Q1 2025, up from 12 in Q4 2024.
- Funds reported $94.7M of Oculis Holding stock for Q1 2025, up 60% quarter-over-quarter.
- 10 funds opened new Oculis Holding positions in Q1 2025 and 2 closed out, a net change of +8 holders.
- The largest Oculis Holding buyer in Q1 2025 was Pivotal bioVenture Partners Investment Advisor, an estimated $11.5M added.
- The largest Oculis Holding seller in Q1 2025 was Citadel Advisors, an estimated $389K sold.
Based on aggregated 13F filings for Q1 2025.